Maetzold also highlighted recent clinical evidence presented at the 2026 American Academy of Dermatology annual meeting. He said new data from 1,868 SEER-linked patients showed the DecisionDx-Melanoma test “significantly stratifies five-year melanoma-specific survival within AJCC stages and T categories,” helping identify patients whose mortality risk is “substantially higher or lower than staging alone would predict.”Despite the first-quarter performance, management reiterated expectations for “mid to high ...